Abstract: P762
Type: Poster
Abstract Category: Therapy - symptomatic - Treatment of specific symptoms
Background and aims: Fampridine is an oral treatment that has been shown to improve walking speed in patients with multiple sclerosis (MS) and a walking disability (EDSS 4-7). The mechanism of action described is an improvement of nerve impulse transmission, blocking potassium channels. We aimed to study the effect of treatment with Fampridine on patients" cognitive performance.
Methods: A prospective study of MS patients aged 18-59, responders to Fampridine. “Responders” were defined by >20% improvement in walking speed after 14 days of treatment. Extensive neuropsychological testing including the Brief Neuropsychological Battery(BNB), forward and reverse digits, the Stroop test and the Trail Making Test(TMT) A and B, as well as the Beck Depression Inventory(BDI), were performed at treatment initiation and 5 months later.
Results: Twelve patients (58% women, mean age 48.8years SD8,6, mean BDI score 10,9) were studied. Overall patients showed an improvement of 38% (SD12,0) in walking speed at 14 days that persisted after 5 months. On cognitive testing, patients showed a trend towards improvement in most cognitive tests performed at 5 months, which was statistically significant for the words Stroop-tests
(p = 0.04), indirect digits (p = 0.029) free delayed recall test and categorical evocation (p = 0.03). No significant differences were found on the BDI scores.
Conclusion: Fampridine-responder MS patients might benefit from treatment with Fampridine beyond the improvement in motor function.
Disclosure:
Dr. Fernández-Fournier: reports no disclosures
Dr. Puertas: reports no disclosures
MS, Chamorro: reports no disclosures
Dr. Tallón Barranco: reports no disclosures
Dr. López Ruiz reports no disclosures
Dr. Lubrini: reports no disclosures.
Abstract: P762
Type: Poster
Abstract Category: Therapy - symptomatic - Treatment of specific symptoms
Background and aims: Fampridine is an oral treatment that has been shown to improve walking speed in patients with multiple sclerosis (MS) and a walking disability (EDSS 4-7). The mechanism of action described is an improvement of nerve impulse transmission, blocking potassium channels. We aimed to study the effect of treatment with Fampridine on patients" cognitive performance.
Methods: A prospective study of MS patients aged 18-59, responders to Fampridine. “Responders” were defined by >20% improvement in walking speed after 14 days of treatment. Extensive neuropsychological testing including the Brief Neuropsychological Battery(BNB), forward and reverse digits, the Stroop test and the Trail Making Test(TMT) A and B, as well as the Beck Depression Inventory(BDI), were performed at treatment initiation and 5 months later.
Results: Twelve patients (58% women, mean age 48.8years SD8,6, mean BDI score 10,9) were studied. Overall patients showed an improvement of 38% (SD12,0) in walking speed at 14 days that persisted after 5 months. On cognitive testing, patients showed a trend towards improvement in most cognitive tests performed at 5 months, which was statistically significant for the words Stroop-tests
(p = 0.04), indirect digits (p = 0.029) free delayed recall test and categorical evocation (p = 0.03). No significant differences were found on the BDI scores.
Conclusion: Fampridine-responder MS patients might benefit from treatment with Fampridine beyond the improvement in motor function.
Disclosure:
Dr. Fernández-Fournier: reports no disclosures
Dr. Puertas: reports no disclosures
MS, Chamorro: reports no disclosures
Dr. Tallón Barranco: reports no disclosures
Dr. López Ruiz reports no disclosures
Dr. Lubrini: reports no disclosures.